Table 2 Correlations between the expression of BMI1, Mel-18, pAkt, p16 proteins and clinicopathologic variables
From: BMI1 and Mel-18 oppositely regulate carcinogenesis and progression of gastric cancer
Variables | Mel-18 n (%) | Â | BMI1 n (%) | Â | pAkt n (%) | Â | p16 n (%) | Â | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Â | (-) | (+) | P value | (-) | (+) | P value | (-) | (+) | P value | (-) | (+) | P value | |
Gender | |||||||||||||
Male | 40(80) | 10(20) | Â | 21(42) | 29(58) | Â | 21(42) | 29(58) | Â | 20(40) | 30(60) | Â | |
Female | 19(76) | 6(24) | 0.6902 | 11(44) | 14(56) | 0.8689 | 12(48) | 13(52) | 0.6217 | 12(48) | 13(52) | 0.509 | |
Age (years) | |||||||||||||
<60 | 27(84.4) | 5(15.6) | Â | 14(43.8) | 18(56.2) | Â | 17(53.1) | 15(46.9) | Â | 15(46.9) | 17(53.1) | Â | |
≥60 | 32(74.4) | 11(25.6) | 0.2979 | 18(41.9) | 25(58.1) | 0.87 | 16(37.2) | 27(62.8) | 0.1696 | 17(39.5) | 26(60.5) | 0.525 | |
Size(cm) | |||||||||||||
<4.5 | 34(81.0) | 8(19.0) | Â | 18(42.9) | 24(57.1) | Â | 20(47.6) | 22(52.4) | Â | 18(42.9) | 24(57.1) | Â | |
≥4.5 | 25(75.8) | 8(24.2) | 0.5857 | 14(42.4) | 19(57.6) | 0.97 | 13(39.4) | 20(60.6) | 0.4763 | 14(42.4) | 19(57.6) | 0.6177 | |
Histology | |||||||||||||
Well differentiated | 23(74.2) | 8(25.8) | Â | 14(45.2) | 17(54.8) | Â | 13(41.9) | 18(58.1) | Â | 12(38.7) | 19(61.3) | Â | |
Poorly differentiated | 36(81.8) | 8(18.2) | 0.4274 | 18(40.9) | 26(59.1) | 0.7139 | 20(45.5) | 24(54.5) | 0.7139 | 20(45.5) | 24(54.5) | 0.5609 | |
T classification | |||||||||||||
T1/2 | 21(84) | 4(16) | Â | 13(52) | 12(48) | Â | 15(60) | 10(40) | Â | 9(36) | 16(64) | Â | |
T3/4 | 38(76) | 12(24) | 0.4253 | 19(38) | 31(62) | 0.2478 | 18(36) | 32(72) | 0.0484* | 23(46) | 27(54) | 0.4091 | |
LNM | |||||||||||||
Negative | 33(80.5) | 8(19.5) | Â | 25(61.0) | 16(39.0) | Â | 24(58.5) | 17(41.5) | Â | 13(31.7) | 28(68.3) | Â | |
Positive | 26(76.5) | 8(23.5) | 0.6725 | 7(20.6) | 27(79.4) | 0.0004* | 9(26.5) | 25(73.5) | 0.0054* | 19(55.9) | 15(44.1) | 0.0351* | |
Distant metastasis | |||||||||||||
Negative | 55(80.9) | 13(19.1) | Â | 31(45.6) | 37(54.4) | Â | 32(47.1) | 36(52.9) | Â | 29(42.6) | 39(57.4) | Â | |
Positive | 4(57.1) | 3(42.9) | 0.1443 | 1(14.3) | 6(85.7) | 0.1108 | 1(14.3) | 6(85.7) | 0.0963 | 3(42.9) | 4(57.1) | 0.9915 | |
Clinical stage | |||||||||||||
I/II | 25(86.2) | 4(13.8) | Â | 18(62.1) | 11(37.9) | Â | 16(57.1) | 12(42.9) | Â | 11(39.3) | 17(60.7) | Â | |
III/IV | 34(73.9) | 12(26.1) | 0.2056 | 14(30.4) | 32(69.6) | 0.007* | 17(36.2) | 30(63.8) | 0.0768 | 21(44.7) | 26(55.3) | 0.6477 | |